Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. is an Israeli biopharmaceutical company with two main business units. The company was incorporated in Israel in 2003 as a privately held company. It completed an initial public offering on the Tel Aviv Stock Exchange (TASE) in February 2007, voluntarily delisting in January 2018. In May 2015, Scinai completed an initial public offering of ADSs and ADSs warrants on the Nasdaq Capital Market. On September 6, 2023, the company changed its corporate name from BiondVax Pharmaceuticals Ltd. to Scinai Immunotherapeutics Ltd. Its principal executive offices are located at Jerusalem BioPark, 2nd floor, Hadassah Ein Kerem Campus, Jerusalem, Israel. The first business unit, Scinai R&D, focuses on developing innovative treatments for inflammation and immunology. The second unit is a contract development and manufacturing organization (CDMO) business, which operates through its subsidiary, Scinai Biopharma Services Ltd. Capital expenditures for the twelve months ended December 31, 2025, and December 31, 2024, were approximately $24 thousand and $12 thousand, respectively. These expenditures were primarily for factory leasehold improvements, computers, and laboratory equipment.